InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (46 ops.)
Browse the complete record of transactions filed by Murphy-Chutorian Douglas, Chief Executive Officer and Director. Insider active across 1 companies, notably Semler Scientific, Inc.. Cumulatively, 61 filings have been published. Total volume traded: €2.5m. The latest transaction was disclosed on 28 February 2022 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations61 total
€3,7562,000 shares@ €1.87820.1% of flow
Common Stock
SEC:0001104659-22-028815:0·
€3,7142,000 shares@ €1.85680.1% of flow
Common Stock
SEC:0001104659-22-026570:0·
€3,7152,000 shares@ €1.85740.1% of flow
Common Stock
SEC:0001104659-22-024238:0·
€3,6662,000 shares@ €1.83320.3% of flow
Common Stock
SEC:0001104659-22-012937·
€3,6662,000 shares@ €1.83320.1% of flow
Common Stock
SEC:0001104659-22-012937:0·
€3,7402,000 shares@ €1.87010.3% of flow
Common Stock
SEC:0001104659-22-010529·
€3,7402,000 shares@ €1.87010.1% of flow
Common Stock
SEC:0001104659-22-010529:0·
€3,7032,000 shares@ €1.85160.3% of flow
Common Stock
SEC:0001104659-22-007952·
€3,7032,000 shares@ €1.85160.1% of flow
Common Stock
SEC:0001104659-22-007952:0·
€3,6812,000 shares@ €1.84040.3% of flow
Common Stock
SEC:0001104659-22-006584·
€3,6812,000 shares@ €1.84040.1% of flow
Common Stock
SEC:0001104659-22-006584:0·
€102,640831 shares@ €123.51448.0% of flow
Common Stock
SEC:0001104659-21-131185·
€102,640831 shares@ €123.51444.0% of flow
Common Stock
SEC:0001104659-21-131185:0·
€11,598100 shares@ €115.98210.9% of flow
Common Stock
SEC:0001104659-21-128106·
€11,598100 shares@ €115.98210.5% of flow
Common Stock
SEC:0001104659-21-128106:0·
€21,924200 shares@ €109.62241.7% of flow
Common Stock
SEC:0001104659-21-125786·
€21,924200 shares@ €109.62240.9% of flow
Common Stock
SEC:0001104659-21-125786:0·
€112,1771,027 shares@ €109.22838.8% of flow
Common Stock
SEC:0001104659-21-123631·
€112,1771,027 shares@ €109.22834.4% of flow
Common Stock
SEC:0001104659-21-123631:0·
€5,15150 shares@ €103.02820.4% of flow
Common Stock
SEC:0001104659-21-120732·
€5,15150 shares@ €103.02820.2% of flow
Common Stock
SEC:0001104659-21-120732:0·
€84,110935 shares@ €89.95696.6% of flow
Common Stock
SEC:0001104659-21-118315·
€84,110935 shares@ €89.95693.3% of flow
Common Stock
SEC:0001104659-21-118315:0·
€87,054950 shares@ €91.63536.8% of flow
Common Stock
SEC:0001104659-21-115931·
€87,054950 shares@ €91.63533.4% of flow
Common Stock
SEC:0001104659-21-115931:0·
25 of 61 declarations
About Murphy-Chutorian Douglas
Douglas Murphy-Chutorian, M.D. is a senior executive closely associated with Semler Scientific, Inc., where he serves as Chief Executive Officer and a member of the board of directors. Company filings show that he has been on the board since September 2012, indicating a long-standing connection to the business and familiarity with its operational, regulatory, and strategic priorities. In April 2023, the board appointed him interim Chief Executive Officer, and subsequent company disclosures describe him as returning to the CEO role on a continuing basis. More recent SEC filings identify him as Chief Executive Officer and Director, and also show that he was appointed interim Chief Financial Officer in October 2025 following the resignation of the prior CFO. His profile reflects a combination of medical background, healthcare industry experience, and public-company leadership in a regulated medtech environment. Publicly available information indicates that he has had a broad and diverse career in healthcare and is trained as a physician. That background suggests expertise at the intersection of clinical understanding, healthcare commercialization, and corporate governance. At Semler Scientific, his role has likely centered on overseeing management continuity, guiding execution, and supporting the company’s strategic decisions in the U.S. public markets. Notable actions during his tenure include his return to executive leadership in 2023, his participation in board-level decision-making, and his involvement in company matters reflected in SEC filings, including capital structure and governance-related events. His leadership profile is therefore best characterized as that of a long-tenured healthcare executive and physician-administrator with significant responsibilities in a Nasdaq-listed company. Given the public record reviewed, the most accurate description remains focused on his CEO and director roles, without attributing additional companies or achievements that are not clearly documented.
